GLP-1 Drugs and SIBO: What the New Research Reveals

Gutter • Mar 2, 2026 • 8 min read

Multiple 2025 studies link GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) to increased SIBO risk, especially after a year of use. Here's what you need to know.

Quick answer

Multiple 2025 studies link GLP-1 receptor agonists (Ozempic, Mounjaro, Wegovy) to increased SIBO risk, especially after a year of use. The mechanism appears to be slowed gastric emptying and altered motility. If you're on these drugs and experiencing new bloating, gas, or altered bowel patterns, SIBO testing may be worth discussing with your clinician.

  • Risk timing: appears elevated within first year of use
  • Mechanism: slowed gastric emptying creates conditions for bacterial overgrowth
  • Action: track symptoms, discuss breath testing with clinician if concerned

The GLP-1 Explosion

GLP-1 receptor agonists have transformed diabetes and obesity treatment. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are now household names. But as usage has exploded, researchers are documenting gut-related side effects that weren't fully visible in earlier trials.

What the New Studies Found

At Digestive Disease Week 2025, multiple research groups presented data on GLP-1 drugs and SIBO:

  • Global retrospective multicenter cohort analysis (PMID: 40941750): First large-scale study identifying increased SIBO incidence with GLP-1/GIP medications
  • Association study (DOI: 10.1177/26345161251353437): GLP-1 receptor agonist use associated with both SIBO and IMO (intestinal methanogen overgrowth)
  • Timing data: Risk appears elevated within the first year of use

The Likely Mechanism

GLP-1 drugs work partly by slowing gastric emptying - that's why people feel full longer and eat less. But slowed transit in the upper GI tract creates conditions where bacteria can overgrow in the small intestine:

  1. Food lingers longer in the small bowel
  2. Bacteria have more time to ferment carbohydrates
  3. Overgrowth establishes and symptoms develop

This is the same mechanism seen in other motility disorders that predispose to SIBO.

Who Should Pay Attention

You might want to discuss SIBO testing with your clinician if:

  • You've been on a GLP-1 drug for 6+ months
  • You're experiencing new or worsening bloating, gas, altered bowel patterns, or abdominal discomfort

What to Do

  • Don't stop your medication without medical guidance - these drugs have important benefits
  • Track your symptoms - when they started, what triggers them
  • Ask your clinician about breath testing - hydrogen/methane breath tests can identify SIBO/IMO
  • Consider motility support - if SIBO is identified, prokinetics may help prevent recurrence

The Bottom Line

GLP-1 drugs are genuinely transformative for many people. But they're not risk-free, and gut motility changes are real. The new research doesn't mean you should avoid them - it means you should be informed and monitor for symptoms.

Sources

  • Diagnostic Evaluation of SIBO Risk with GLP-1/GIP Agonists (PMID: 40941750)
  • GLP-1 Receptor Agonist Use Associated with SIBO and IMO (DOI: 10.1177/26345161251353437)
  • DDW 2025 Poster Presentations on GLP-1 and SIBO

Medical disclaimer: This article is educational only and not medical advice. Consult your healthcare provider before changing any medication regimen.